Objective: Worldwide genetic counseling practices are variable and often not reported in low- and middle-income countries (LMICs). We present the follow-up genetic counseling, breast screening, risk-reducing salpingo-oophorectomy (RRSO) and contralateral prophylactic mastectomy (CPM) in a cohort of study patients with either pathogenic mutations or variant of unknown significance (VUS).

Materials And Methods: Chart review and phone calls for the collection of information. Out of a cohort of 250 patients, 14 had deleterious mutations and 31 had a VUS, of whom 19 had primary early breast cancer. We collected information about genetic counseling, screening, CPM and RRSO.

Results: Fourteen patients with deleterious mutations (7 and 7 ) and 19 patients with VUS mutations (20 VUS, 4 , 16 ; 1 patient had both) were surveyed. Of 14 patients with deleterious mutations, 57.14% (8/14 patients) received genetic counseling from their oncologist. Subsequently 85.71% (12/14) are undergoing mammography screening and 35.71% (5/14) breast screening magnetic resonance imaging (MRI). Furthermore, 50% of them underwent CPM and 57.14% underwent RRSO. Of 19 patients with VUS mutations, 10.5% received genetic counseling from their oncologist; 78.9% were undergoing regular screening mammogram and 31.5% were undergoing breast MRI; one patient underwent CPM and two patients RRSO.

Conclusion: Within three years from knowing they have a mutation, 50% of patients with germline mutations had undergone CPM and 60% RRSO, the majority of them had screening mammography surveillance but only 50% had screening MRI. Follow-up of patients with VUS with mammography was 78% but MRI was only 31%. Lack of MRI surveillance reflects both limited resources and insufficient counseling. Genetic counseling was done by medical oncologists, which reflects a trend in LMIC. Our Data shows the importance of the need for professional genetic counselors and optimal surveillance in Lebanon and other LMICs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734520PMC
http://dx.doi.org/10.4274/ejbh.galenos.2021.2021-5-1DOI Listing

Publication Analysis

Top Keywords

genetic counseling
28
patients deleterious
12
deleterious mutations
12
patients vus
12
patients
11
genetic
8
screening
8
counseling screening
8
screening risk-reducing
8
breast cancer
8

Similar Publications

Background: Previously, the Penn Frontotemporal Degeneration (FTD) Center developed and validated criteria to stratify pedigrees of patients with FTD by likelihood of identifying a genetic etiology (Wood, JAMA Neurol., 2013). Pedigrees were classified as high-risk, medium-risk, low-risk, apparent sporadic, or unknown significance.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Amsterdam UMC location VUmc, Amsterdam, Noord-holland, Netherlands.

Background: SORL1 encodes the retromer-associated receptor SORLA that functions in endosomal recycling. Rare variants in SORL1 have been associated with Alzheimer's disease (AD) and rare pathogenic variants are estimated to occur in up to 2.75% of early onset AD patients and in 1.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) risk is markedly increased among APOE ε4/ε4 homozygotes. Previous studies of APOE genotype disclosure impact have included few ethnic minorities. This study addresses this gap by investigating the immediate impact of disclosing an APOE ε4/ε4 genotype in the Información de la Enfermedad de Alzheimer para Latinos (IDEAL) study, a Latino community-based study.

View Article and Find Full Text PDF

Background: Gaining insight into the emotional consequences of disclosing amyloid Positron Emission Tomography (PET) results is essential for offering effective support to patients of varying cognitive status. This analysis aimed to examine variations in emotional distress levels following the disclosure of amyloid PET results among participants that are cognitively normal, with Mild Cognitive Impairment (MCI), or dementia.

Method: This investigation was a preliminary analysis of 55 participants, using 1-month follow-up call data of an ongoing brain imaging data repository study, obtaining baseline PET imaging on a subset of Alzheimer's Disease Research Center (ADRC) participants.

View Article and Find Full Text PDF

Routine Prenatal cfDNA Screening for Autosomal Dominant Single-Gene Conditions.

Clin Chem

January 2025

Division of Maternal-Fetal-Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

Background: Genetic screening has advanced from prenatal cell-free DNA (cfDNA) screening for aneuploidies (cfDNA-ANP) to single-gene disorders (cfDNA-SGD). Clinical validation studies have been promising in pregnancies with anomalies but are limited in the general population.

Methods: Chart review and laboratory data identified pregnancies with cfDNA-SGD screening for 25 autosomal dominant conditions at our academic center.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!